Clinical TrialID 8205
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
NCT05844150
SCLC
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 8205
- Evidence Id
- 8205
- Core Evidence Id
- 8205
- Source Clinical Trial Id
- 8203
- Herb2 Clinical Trial Id
- HBCT008203
- Nct Id
- NCT05844150
- Title
- A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
- Status
- Recruiting
- Phase
- Phase 2|Phase 3
- Study Result
- No
- Study Condition
- SCLC
- Study Type
- Interventional
- Study Design
- Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
- Intervention
- DRUG: PM8002|DRUG: Platinum|DRUG: Atezolizumab|DRUG: Etoposide
- Intervention Allocation
- Randomized
- Intervention Model
- Parallel
- Intervention Mask
- Double
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 445
- Outcome Measure
- Objective response rate (Part 1), Objective response rate (ORR) is the proportion of subjects with complete response (CR) or partial response (PR), based on RECIST v1.1., Up to approximately 2 years|Overall survival (Part 2), Overall survival (OS) is the time from the date of randomization or first dosing date to death due to any cause., Up to approximately 2 years
- Sponsor Collaborator
- Biotheus Inc.
- Funded By
- INDUSTRY
- Location
- Jilin Cancer Hospital, Changchun, China
- Other Id
- PM8002-BC011C-SCLC-R
- Start Date
- 2023-06-01
- Primary Completion Date
- 2025-06
- Completion Date
- 2025-12
- First Posted
- 2023-05-06
- Results First Posted
- Last Update Posted
- 2024-09-05
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT05844150
- Title Cn
- Title En
- A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
- Bilingual Status
- semi_complete